​

Zevra Therapeutics (ZVRA) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChartTranscripts

ZVRA Stock Forecast

Zevra Therapeutics (ZVRA) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $21.00, with a high of $25.00 and a low of $17.00. This represents a 167.18% increase from the last price of $7.86.

- $5 $10 $15 $20 $25 High: $25 Avg: $21 Low: $17 Last Closed Price: $7.86

ZVRA Stock Rating

Zevra Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (88.89%), 1 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 8 Strong Sell Sell Hold Buy Strong Buy

ZVRA Forecast vs Benchmarks

TypeNameUpside
StockZevra Therapeutics167.18%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$21.00
Last Closing Price$7.86$7.86$7.86
Upside/Downside--167.18%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2544---8
Dec, 2444---8
Nov, 2445---9
Oct, 2445---9
Sep, 2445---9
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 24, 2024Jonathan AschoffRoth Capital$21.00$7.58177.04%167.18%
Sep 24, 2024Jason McCarthyMaxim Group$25.00$7.58229.82%218.07%
Sep 24, 2024Jason ButlerJMP Securities$17.00$7.58124.27%116.28%
Sep 23, 2024Oren LivnatH.C. Wainwright$20.00$7.92152.53%154.45%
Sep 18, 2024Sumant KulkarniCanaccord Genuity$22.00$7.53192.16%179.90%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 07, 2024GuggenheimBuyinitialise
Sep 24, 2024Maxim GroupMarket OutperformMarket Outperformhold
Sep 24, 2024Maxim GroupBuyBuyhold
Sep 24, 2024JMP SecuritiesMarket OutperformOutperforminitialise
Sep 24, 2024JMP SecuritiesMarket Outperforminitialise
Sep 20, 2024H.C. WainwrightBuyBuyhold
Sep 18, 2024Canaccord GenuityBuyBuyhold
Aug 05, 2024H.C. WainwrightBuyBuyhold
Jun 10, 2024Cantor FitzgeraldOverweightOverweighthold
Dec 28, 2023Canaccord GenuityBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.21$-0.29$-1.20$-1.30-----
Avg Forecast$-2.75$-0.86$-1.12$-1.18$-1.89$-0.57$0.78$2.11$3.14
High Forecast$-3.59$-1.12$-1.67$-1.35$-1.94$-6.74$0.27$1.44$2.13
Low Forecast$-1.92$-0.60$-0.77$-1.07$-1.86$2.51$1.42$3.14$4.80
Surprise %16.73%-66.28%7.14%10.17%-----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$13.29M$28.65M$10.46M$27.46M-----
Avg Forecast$12.88M$28.30M$11.24M$25.98M$20.46M$98.27M$174.66M$268.80M$349.60M
High Forecast$9.89M$21.72M$8.56M$25.84M$20.01M$88.12M$174.66M$202.11M$262.87M
Low Forecast$15.91M$34.95M$15.52M$26.25M$20.71M$105.52M$174.66M$377.84M$491.43M
Surprise %3.13%1.23%-6.96%5.70%-----

Net Income Forecast

$-250M $-160M $-70M $20M $110M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-12.76M$-8.55M$-41.54M$-46.05M-----
Avg Forecast$-97.49M$-30.31M$-39.53M$-46.05M$-67.48M$2.45M$44.53M$81.06M$111.32M
High Forecast$-127.26M$-39.57M$-59.11M$-47.84M$-68.86M$-238.83M$9.67M$50.91M$75.42M
Low Forecast$-68.00M$-21.14M$-27.29M$-37.90M$-66.11M$88.93M$50.19M$111.21M$170.03M
Surprise %-86.91%-71.78%5.09%------

ZVRA Forecast FAQ

Is Zevra Therapeutics stock a buy?

Zevra Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Zevra Therapeutics is a favorable investment for most analysts.

What is Zevra Therapeutics's price target?

Zevra Therapeutics's price target, set by 9 Wall Street analysts, averages $21 over the next 12 months. The price target range spans from $17 at the low end to $25 at the high end, suggesting a potential 167.18% change from the previous close price of $7.86.

How does Zevra Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Zevra Therapeutics stock forecast shows a 167.18% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Zevra Therapeutics over the past three months?

  • January 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Zevra Therapeutics’s EPS forecast?

Zevra Therapeutics's average annual EPS forecast for its fiscal year ending in December is -1.89 for 2024, a 45.38% increase from the reported $-1.3 in 2023. The prediction for 2025 is $-0.57, $0.78 for 2026, $2.11 for 2027, and $3.14 for 2028.

What is Zevra Therapeutics’s revenue forecast?

Zevra Therapeutics's average annual revenue forecast for its fiscal year ending in December is $20.46M for 2024, a -25.50% decrease from the reported $27.46M in 2023. The forecast for 2025 is $98.27M, $174.66M for 2026, $268.8M for 2027, and $349.6M for 2028.

What is Zevra Therapeutics’s net income forecast?

For its fiscal year ending in December, Zevra Therapeutics's average annual net income forecast is $-67.483M for 2024, reflecting an 46.55% increase from the reported $-46.049M in 2023. The projection for 2025 is $2.45M, $44.53M for 2026, $81.06M for 2027, and $111.32M for 2028.